Abstract
The goal of diabetes treatment is not only reducing glycaemia, but especially reducing the risk of developing micro- and macrovascular complications of diabetes and patient satisfaction. In the treatment of diabetes, as in other fields of medicine, the principle of individuation is recommended.
Currently, a steadily rising numbers of antidiabetic agents divided into many categories appear, and we have to choose from. Treatment of type 2 diabetes has thus now become more complicated, but significantly more effective than previously.
Of course, it is not easy to choose the most appropriate treatment for a patient. Choice of therapy, according to various criteria, we are always available and we should choose the most suitable option, which will improve the compensation, ideally to achieve the targets, but at the same time improve or maintain the quality of life remains a patient with diabetes.
Reduction in glycosylated hemoglobin levels is no longer enough, the basic requirements for the new antidiabetic drugs include security, particularly in terms of the risk of hypoglycemia and cardiovascular safety.